

“Rapid review” methodology to inform a policy decision: when is it fit for purpose?

A case study

Alexis Llewellyn, Mark Simmonds, Ginny Brunton, James Thomas , Amanda Sowden

COI statement: I have no actual or potential conflict of interest in relation to this presentation.

Funding source: UK Department of Health, Policy Research Programme

Background

- Inform policy on **compensation** for patients with **HIV & Hep C** from contaminated blood products

Review

- **10 weeks** review: **antiretroviral therapy** on **liver-related** outcomes in HIV/Hep C patients

Aim

- Explore implications of “rapid review” methods for **research** and **policy**

Our “rapid review” methods

Risk of publication bias!

Risk of reviewer error and bias!

	Our review	Cochrane review
Search	Medline & Embase, citations search, no unpublished studies	At least Medline, Embase and CENTRAL
Study selection (T&A)	1 reviewer	≥2 independent reviewers
Study selection (FT)	2 reviewers	
Data extraction	1+1 checker	
Risk of Bias	1+1 checker	
Patient & public involvement (PPI)	1 patient group	None to extended

Risk of limited relevance!

Results & conclusions

- 13 observational studies, 6 in M-A


- Conclusion

- Limitations

- of evidence: No RCTs & high RoB
- of review: risk of missing studies



But how much did this matter?



Exploring impact of review limitations: 2 scenarios

Assuming the review missed relevant studies, what additional evidence would a “gold-standard” review need to change the conclusions?

Fig a.





Fig b.



How likely?

Final words

“How much additional evidence would be needed to change the conclusions?”

**Appraisal of review methods is
always context dependent**

What mattered most here: limited review methods, lack of RCTs, or limited PPI?

*Were our methods **fit for purpose?***